Global Isothermal Nucleic Acid Amplification Technology Inaat Market
Global Isothermal Nucleic Acid Amplification Technology Inaat Market

Isothermal Nucleic Acid Amplification Technology Inaat Comprehensive Study by Type (Instruments, Reagents), Application (Infectious Disease Diagnosis (HIV, Influenza), Blood Screening, Others), Technology (Helicase-dependent Amplification (HDA), Nicking Enzyme Amplification Reaction (NEAR), Loop-mediated Isothermal Amplification (LAMP), Strand Displacement Amplification (SDA), Nucleic Acid Sequence-based Amplification (NASBA), Transcription Mediated Amplification (TMA), Single Primer Isothermal Amplification (SPIA), Other Technologies), End-User (Hospital, Clinic, Research Institute, Others) Players and Region - Global Market Outlook to 2025

Isothermal Nucleic Acid Amplification Technology Inaat Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

May 2020 Edition 250 Pages 212 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Isothermal Nucleic Acid Amplification Technology Inaat Market Overview:
The factors that are favoring the development of the novel applications of nucleic acid are molecular diagnostics, nanoparticle diagnostics, and laboratory research. It is firstly compiled with the intent of highlighting the prevalent dynamics and the growth opportunities in the global isothermal nucleic acid amplification technology market. By the standards set up by the World Health Organization (WHO), an ideal form of RNA/DNA diagnostic test kit that usually includes the polymerase chain reaction (PCR) instruments, should be cost-effective, highly accurate, and customizable so as to cater to the specific user requirements. Furthermore, it is also very necessary for the diagnostic test kits to be slightly less complicated but tough at the very same time. All in all, the demand for the instruments that are providing quick as well as precise results of the diagnosis is considered very high. With the advent of the non-PCR technology like the INAAT, it is thus gaining power from the various research communities as it complies with all of the criteria specified by the WHO. With a slight mending in the parameters, INAAT can further be customized so as to suit the different measurement requirements, thus facilitating the Point-of-Care Testing (POCT), meanwhile also operating within the economic standards as set by the WHO.

Market Drivers
  • Growing Presence Of A Well-Established Healthcare System
  • The Rising Disposable Income And Healthcare Infrastructure Modernization
  • Growing Awareness Among Physicians And Healthcare Professionals About The Benefits Of Gene-Based Disease Diagnosis And Treatment

Market Trend
  • A Rise In The Access To Technologically Advanced Diagnostics And Techniques
  • The Rising Number Of Genome-Based Drug Development Activities

Restraints
  • High Cost of the Isothermal Nucleic Acid Amplification Technology

Opportunities
  • The Availability Of Research And Development Funding For Genomics Research

Challenges
  • Unawareness About the Technology in Developing Regions


Competitive Landscape:
The companies are now exploring the market by adopting mergers & acquisitions, expansions, investments, new developments in existing products, and collaborations as their preferred strategies. The players are also exploring new geographies and industries through expansions and acquisitions so as to avail a competitive advantage through combined synergies.
Some of the key players profiled in the report are Grifols S.A. (Spain), Hologic, Inc. (United States), Abbott Laboratories, Inc. (United States), Becton, Dickinson & Company (United States), Quidel Corporation (United States), Meridian Bioscience (United States), Eiken Chemical Co. Ltd. (Japan), Lucigen Corporation (United States), OptiGene Limited (United Kingdom), bioMerieux SA (France) and Qiagen (Netherlands). Additionally, following companies can also be profiled that are part of our coverage like Sysmex Corporation (Japan), PREMIER Biosoft (United States) and mFluiDx (United States). Analyst at AdvanceMarketAnalytics see United States Players to retain maximum share of Global Isothermal Nucleic Acid Amplification Technology Inaat market by 2025. Considering Market by Technology, the sub-segment i.e. Helicase-dependent Amplification (HDA) will boost the Isothermal Nucleic Acid Amplification Technology Inaat market. Considering Market by End-User, the sub-segment i.e. Hospital will boost the Isothermal Nucleic Acid Amplification Technology Inaat market.

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Isothermal Nucleic Acid Amplification Technology Inaat market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Isothermal Nucleic Acid Amplification Technology Inaat market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Providers of Isothermal Nucleic Acid Amplification Technology, End-Users, Potential Investors, Market Research Firms and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.
Report Objectives / Segmentation Covered
By Type
  • Instruments
  • Reagents
By Application
  • Infectious Disease Diagnosis [HIV, Influenza]
  • Blood Screening
  • Others
By Technology
  • Helicase-dependent Amplification (HDA)
  • Nicking Enzyme Amplification Reaction (NEAR)
  • Loop-mediated Isothermal Amplification (LAMP)
  • Strand Displacement Amplification (SDA)
  • Nucleic Acid Sequence-based Amplification (NASBA)
  • Transcription Mediated Amplification (TMA)
  • Single Primer Isothermal Amplification (SPIA)
  • Other Technologies

By End-User
  • Hospital
  • Clinic
  • Research Institute
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Presence Of A Well-Established Healthcare System
      • 3.2.2. The Rising Disposable Income And Healthcare Infrastructure Modernization
      • 3.2.3. Growing Awareness Among Physicians And Healthcare Professionals About The Benefits Of Gene-Based Disease Diagnosis And Treatment
    • 3.3. Market Challenges
      • 3.3.1. Unawareness About the Technology in Developing Regions
    • 3.4. Market Trends
      • 3.4.1. A Rise In The Access To Technologically Advanced Diagnostics And Techniques
      • 3.4.2. The Rising Number Of Genome-Based Drug Development Activities
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Isothermal Nucleic Acid Amplification Technology Inaat, by Type, Application, Technology, End-User and Region (value and price ) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Isothermal Nucleic Acid Amplification Technology Inaat (Value)
      • 5.2.1. Global Isothermal Nucleic Acid Amplification Technology Inaat by: Type (Value)
        • 5.2.1.1. Instruments
        • 5.2.1.2. Reagents
      • 5.2.2. Global Isothermal Nucleic Acid Amplification Technology Inaat by: Application (Value)
        • 5.2.2.1. Infectious Disease Diagnosis [HIV, Influenza]
        • 5.2.2.2. Blood Screening
        • 5.2.2.3. Others
      • 5.2.3. Global Isothermal Nucleic Acid Amplification Technology Inaat by: Technology (Value)
        • 5.2.3.1. Helicase-dependent Amplification (HDA)
        • 5.2.3.2. Nicking Enzyme Amplification Reaction (NEAR)
        • 5.2.3.3. Loop-mediated Isothermal Amplification (LAMP)
        • 5.2.3.4. Strand Displacement Amplification (SDA)
        • 5.2.3.5. Nucleic Acid Sequence-based Amplification (NASBA)
        • 5.2.3.6. Transcription Mediated Amplification (TMA)
        • 5.2.3.7. Single Primer Isothermal Amplification (SPIA)
        • 5.2.3.8. Other Technologies
      • 5.2.4. Global Isothermal Nucleic Acid Amplification Technology Inaat by: End-User (Value)
        • 5.2.4.1. Hospital
        • 5.2.4.2. Clinic
        • 5.2.4.3. Research Institute
        • 5.2.4.4. Others
      • 5.2.5. Global Isothermal Nucleic Acid Amplification Technology Inaat Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Isothermal Nucleic Acid Amplification Technology Inaat (Price)
      • 5.3.1. Global Isothermal Nucleic Acid Amplification Technology Inaat by: Type (Price)
  • 6. Isothermal Nucleic Acid Amplification Technology Inaat: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Grifols S.A. (Spain)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Hologic, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Abbott Laboratories, Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Becton, Dickinson & Company (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Quidel Corporation (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Meridian Bioscience (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Eiken Chemical Co. Ltd. (Japan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Lucigen Corporation (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. OptiGene Limited (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. BioMerieux SA (France)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Qiagen (Netherlands)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Isothermal Nucleic Acid Amplification Technology Inaat Sale, by Type, Application, Technology, End-User and Region (value and price ) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Isothermal Nucleic Acid Amplification Technology Inaat (Value)
      • 7.2.1. Global Isothermal Nucleic Acid Amplification Technology Inaat by: Type (Value)
        • 7.2.1.1. Instruments
        • 7.2.1.2. Reagents
      • 7.2.2. Global Isothermal Nucleic Acid Amplification Technology Inaat by: Application (Value)
        • 7.2.2.1. Infectious Disease Diagnosis [HIV, Influenza]
        • 7.2.2.2. Blood Screening
        • 7.2.2.3. Others
      • 7.2.3. Global Isothermal Nucleic Acid Amplification Technology Inaat by: Technology (Value)
        • 7.2.3.1. Helicase-dependent Amplification (HDA)
        • 7.2.3.2. Nicking Enzyme Amplification Reaction (NEAR)
        • 7.2.3.3. Loop-mediated Isothermal Amplification (LAMP)
        • 7.2.3.4. Strand Displacement Amplification (SDA)
        • 7.2.3.5. Nucleic Acid Sequence-based Amplification (NASBA)
        • 7.2.3.6. Transcription Mediated Amplification (TMA)
        • 7.2.3.7. Single Primer Isothermal Amplification (SPIA)
        • 7.2.3.8. Other Technologies
      • 7.2.4. Global Isothermal Nucleic Acid Amplification Technology Inaat by: End-User (Value)
        • 7.2.4.1. Hospital
        • 7.2.4.2. Clinic
        • 7.2.4.3. Research Institute
        • 7.2.4.4. Others
      • 7.2.5. Global Isothermal Nucleic Acid Amplification Technology Inaat Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Isothermal Nucleic Acid Amplification Technology Inaat (Price)
      • 7.3.1. Global Isothermal Nucleic Acid Amplification Technology Inaat by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Isothermal Nucleic Acid Amplification Technology Inaat: by Type(USD Million)
  • Table 2. Isothermal Nucleic Acid Amplification Technology Inaat Instruments , by Region USD Million (2014-2019)
  • Table 3. Isothermal Nucleic Acid Amplification Technology Inaat Reagents , by Region USD Million (2014-2019)
  • Table 4. Isothermal Nucleic Acid Amplification Technology Inaat: by Application(USD Million)
  • Table 5. Isothermal Nucleic Acid Amplification Technology Inaat Infectious Disease Diagnosis [HIV, Influenza] , by Region USD Million (2014-2019)
  • Table 6. Isothermal Nucleic Acid Amplification Technology Inaat Blood Screening , by Region USD Million (2014-2019)
  • Table 7. Isothermal Nucleic Acid Amplification Technology Inaat Others , by Region USD Million (2014-2019)
  • Table 8. Isothermal Nucleic Acid Amplification Technology Inaat: by Technology(USD Million)
  • Table 9. Isothermal Nucleic Acid Amplification Technology Inaat Helicase-dependent Amplification (HDA) , by Region USD Million (2014-2019)
  • Table 10. Isothermal Nucleic Acid Amplification Technology Inaat Nicking Enzyme Amplification Reaction (NEAR) , by Region USD Million (2014-2019)
  • Table 11. Isothermal Nucleic Acid Amplification Technology Inaat Loop-mediated Isothermal Amplification (LAMP) , by Region USD Million (2014-2019)
  • Table 12. Isothermal Nucleic Acid Amplification Technology Inaat Strand Displacement Amplification (SDA) , by Region USD Million (2014-2019)
  • Table 13. Isothermal Nucleic Acid Amplification Technology Inaat Nucleic Acid Sequence-based Amplification (NASBA) , by Region USD Million (2014-2019)
  • Table 14. Isothermal Nucleic Acid Amplification Technology Inaat Transcription Mediated Amplification (TMA) , by Region USD Million (2014-2019)
  • Table 15. Isothermal Nucleic Acid Amplification Technology Inaat Single Primer Isothermal Amplification (SPIA) , by Region USD Million (2014-2019)
  • Table 16. Isothermal Nucleic Acid Amplification Technology Inaat Other Technologies , by Region USD Million (2014-2019)
  • Table 17. Isothermal Nucleic Acid Amplification Technology Inaat: by End-User(USD Million)
  • Table 18. Isothermal Nucleic Acid Amplification Technology Inaat Hospital , by Region USD Million (2014-2019)
  • Table 19. Isothermal Nucleic Acid Amplification Technology Inaat Clinic , by Region USD Million (2014-2019)
  • Table 20. Isothermal Nucleic Acid Amplification Technology Inaat Research Institute , by Region USD Million (2014-2019)
  • Table 21. Isothermal Nucleic Acid Amplification Technology Inaat Others , by Region USD Million (2014-2019)
  • Table 22. South America Isothermal Nucleic Acid Amplification Technology Inaat, by Country USD Million (2014-2019)
  • Table 23. South America Isothermal Nucleic Acid Amplification Technology Inaat, by Type USD Million (2014-2019)
  • Table 24. South America Isothermal Nucleic Acid Amplification Technology Inaat, by Application USD Million (2014-2019)
  • Table 25. South America Isothermal Nucleic Acid Amplification Technology Inaat, by Technology USD Million (2014-2019)
  • Table 26. South America Isothermal Nucleic Acid Amplification Technology Inaat, by End-User USD Million (2014-2019)
  • Table 27. Brazil Isothermal Nucleic Acid Amplification Technology Inaat, by Type USD Million (2014-2019)
  • Table 28. Brazil Isothermal Nucleic Acid Amplification Technology Inaat, by Application USD Million (2014-2019)
  • Table 29. Brazil Isothermal Nucleic Acid Amplification Technology Inaat, by Technology USD Million (2014-2019)
  • Table 30. Brazil Isothermal Nucleic Acid Amplification Technology Inaat, by End-User USD Million (2014-2019)
  • Table 31. Argentina Isothermal Nucleic Acid Amplification Technology Inaat, by Type USD Million (2014-2019)
  • Table 32. Argentina Isothermal Nucleic Acid Amplification Technology Inaat, by Application USD Million (2014-2019)
  • Table 33. Argentina Isothermal Nucleic Acid Amplification Technology Inaat, by Technology USD Million (2014-2019)
  • Table 34. Argentina Isothermal Nucleic Acid Amplification Technology Inaat, by End-User USD Million (2014-2019)
  • Table 35. Rest of South America Isothermal Nucleic Acid Amplification Technology Inaat, by Type USD Million (2014-2019)
  • Table 36. Rest of South America Isothermal Nucleic Acid Amplification Technology Inaat, by Application USD Million (2014-2019)
  • Table 37. Rest of South America Isothermal Nucleic Acid Amplification Technology Inaat, by Technology USD Million (2014-2019)
  • Table 38. Rest of South America Isothermal Nucleic Acid Amplification Technology Inaat, by End-User USD Million (2014-2019)
  • Table 39. Asia Pacific Isothermal Nucleic Acid Amplification Technology Inaat, by Country USD Million (2014-2019)
  • Table 40. Asia Pacific Isothermal Nucleic Acid Amplification Technology Inaat, by Type USD Million (2014-2019)
  • Table 41. Asia Pacific Isothermal Nucleic Acid Amplification Technology Inaat, by Application USD Million (2014-2019)
  • Table 42. Asia Pacific Isothermal Nucleic Acid Amplification Technology Inaat, by Technology USD Million (2014-2019)
  • Table 43. Asia Pacific Isothermal Nucleic Acid Amplification Technology Inaat, by End-User USD Million (2014-2019)
  • Table 44. China Isothermal Nucleic Acid Amplification Technology Inaat, by Type USD Million (2014-2019)
  • Table 45. China Isothermal Nucleic Acid Amplification Technology Inaat, by Application USD Million (2014-2019)
  • Table 46. China Isothermal Nucleic Acid Amplification Technology Inaat, by Technology USD Million (2014-2019)
  • Table 47. China Isothermal Nucleic Acid Amplification Technology Inaat, by End-User USD Million (2014-2019)
  • Table 48. Japan Isothermal Nucleic Acid Amplification Technology Inaat, by Type USD Million (2014-2019)
  • Table 49. Japan Isothermal Nucleic Acid Amplification Technology Inaat, by Application USD Million (2014-2019)
  • Table 50. Japan Isothermal Nucleic Acid Amplification Technology Inaat, by Technology USD Million (2014-2019)
  • Table 51. Japan Isothermal Nucleic Acid Amplification Technology Inaat, by End-User USD Million (2014-2019)
  • Table 52. India Isothermal Nucleic Acid Amplification Technology Inaat, by Type USD Million (2014-2019)
  • Table 53. India Isothermal Nucleic Acid Amplification Technology Inaat, by Application USD Million (2014-2019)
  • Table 54. India Isothermal Nucleic Acid Amplification Technology Inaat, by Technology USD Million (2014-2019)
  • Table 55. India Isothermal Nucleic Acid Amplification Technology Inaat, by End-User USD Million (2014-2019)
  • Table 56. South Korea Isothermal Nucleic Acid Amplification Technology Inaat, by Type USD Million (2014-2019)
  • Table 57. South Korea Isothermal Nucleic Acid Amplification Technology Inaat, by Application USD Million (2014-2019)
  • Table 58. South Korea Isothermal Nucleic Acid Amplification Technology Inaat, by Technology USD Million (2014-2019)
  • Table 59. South Korea Isothermal Nucleic Acid Amplification Technology Inaat, by End-User USD Million (2014-2019)
  • Table 60. Taiwan Isothermal Nucleic Acid Amplification Technology Inaat, by Type USD Million (2014-2019)
  • Table 61. Taiwan Isothermal Nucleic Acid Amplification Technology Inaat, by Application USD Million (2014-2019)
  • Table 62. Taiwan Isothermal Nucleic Acid Amplification Technology Inaat, by Technology USD Million (2014-2019)
  • Table 63. Taiwan Isothermal Nucleic Acid Amplification Technology Inaat, by End-User USD Million (2014-2019)
  • Table 64. Australia Isothermal Nucleic Acid Amplification Technology Inaat, by Type USD Million (2014-2019)
  • Table 65. Australia Isothermal Nucleic Acid Amplification Technology Inaat, by Application USD Million (2014-2019)
  • Table 66. Australia Isothermal Nucleic Acid Amplification Technology Inaat, by Technology USD Million (2014-2019)
  • Table 67. Australia Isothermal Nucleic Acid Amplification Technology Inaat, by End-User USD Million (2014-2019)
  • Table 68. Rest of Asia-Pacific Isothermal Nucleic Acid Amplification Technology Inaat, by Type USD Million (2014-2019)
  • Table 69. Rest of Asia-Pacific Isothermal Nucleic Acid Amplification Technology Inaat, by Application USD Million (2014-2019)
  • Table 70. Rest of Asia-Pacific Isothermal Nucleic Acid Amplification Technology Inaat, by Technology USD Million (2014-2019)
  • Table 71. Rest of Asia-Pacific Isothermal Nucleic Acid Amplification Technology Inaat, by End-User USD Million (2014-2019)
  • Table 72. Europe Isothermal Nucleic Acid Amplification Technology Inaat, by Country USD Million (2014-2019)
  • Table 73. Europe Isothermal Nucleic Acid Amplification Technology Inaat, by Type USD Million (2014-2019)
  • Table 74. Europe Isothermal Nucleic Acid Amplification Technology Inaat, by Application USD Million (2014-2019)
  • Table 75. Europe Isothermal Nucleic Acid Amplification Technology Inaat, by Technology USD Million (2014-2019)
  • Table 76. Europe Isothermal Nucleic Acid Amplification Technology Inaat, by End-User USD Million (2014-2019)
  • Table 77. Germany Isothermal Nucleic Acid Amplification Technology Inaat, by Type USD Million (2014-2019)
  • Table 78. Germany Isothermal Nucleic Acid Amplification Technology Inaat, by Application USD Million (2014-2019)
  • Table 79. Germany Isothermal Nucleic Acid Amplification Technology Inaat, by Technology USD Million (2014-2019)
  • Table 80. Germany Isothermal Nucleic Acid Amplification Technology Inaat, by End-User USD Million (2014-2019)
  • Table 81. France Isothermal Nucleic Acid Amplification Technology Inaat, by Type USD Million (2014-2019)
  • Table 82. France Isothermal Nucleic Acid Amplification Technology Inaat, by Application USD Million (2014-2019)
  • Table 83. France Isothermal Nucleic Acid Amplification Technology Inaat, by Technology USD Million (2014-2019)
  • Table 84. France Isothermal Nucleic Acid Amplification Technology Inaat, by End-User USD Million (2014-2019)
  • Table 85. Italy Isothermal Nucleic Acid Amplification Technology Inaat, by Type USD Million (2014-2019)
  • Table 86. Italy Isothermal Nucleic Acid Amplification Technology Inaat, by Application USD Million (2014-2019)
  • Table 87. Italy Isothermal Nucleic Acid Amplification Technology Inaat, by Technology USD Million (2014-2019)
  • Table 88. Italy Isothermal Nucleic Acid Amplification Technology Inaat, by End-User USD Million (2014-2019)
  • Table 89. United Kingdom Isothermal Nucleic Acid Amplification Technology Inaat, by Type USD Million (2014-2019)
  • Table 90. United Kingdom Isothermal Nucleic Acid Amplification Technology Inaat, by Application USD Million (2014-2019)
  • Table 91. United Kingdom Isothermal Nucleic Acid Amplification Technology Inaat, by Technology USD Million (2014-2019)
  • Table 92. United Kingdom Isothermal Nucleic Acid Amplification Technology Inaat, by End-User USD Million (2014-2019)
  • Table 93. Netherlands Isothermal Nucleic Acid Amplification Technology Inaat, by Type USD Million (2014-2019)
  • Table 94. Netherlands Isothermal Nucleic Acid Amplification Technology Inaat, by Application USD Million (2014-2019)
  • Table 95. Netherlands Isothermal Nucleic Acid Amplification Technology Inaat, by Technology USD Million (2014-2019)
  • Table 96. Netherlands Isothermal Nucleic Acid Amplification Technology Inaat, by End-User USD Million (2014-2019)
  • Table 97. Rest of Europe Isothermal Nucleic Acid Amplification Technology Inaat, by Type USD Million (2014-2019)
  • Table 98. Rest of Europe Isothermal Nucleic Acid Amplification Technology Inaat, by Application USD Million (2014-2019)
  • Table 99. Rest of Europe Isothermal Nucleic Acid Amplification Technology Inaat, by Technology USD Million (2014-2019)
  • Table 100. Rest of Europe Isothermal Nucleic Acid Amplification Technology Inaat, by End-User USD Million (2014-2019)
  • Table 101. MEA Isothermal Nucleic Acid Amplification Technology Inaat, by Country USD Million (2014-2019)
  • Table 102. MEA Isothermal Nucleic Acid Amplification Technology Inaat, by Type USD Million (2014-2019)
  • Table 103. MEA Isothermal Nucleic Acid Amplification Technology Inaat, by Application USD Million (2014-2019)
  • Table 104. MEA Isothermal Nucleic Acid Amplification Technology Inaat, by Technology USD Million (2014-2019)
  • Table 105. MEA Isothermal Nucleic Acid Amplification Technology Inaat, by End-User USD Million (2014-2019)
  • Table 106. Middle East Isothermal Nucleic Acid Amplification Technology Inaat, by Type USD Million (2014-2019)
  • Table 107. Middle East Isothermal Nucleic Acid Amplification Technology Inaat, by Application USD Million (2014-2019)
  • Table 108. Middle East Isothermal Nucleic Acid Amplification Technology Inaat, by Technology USD Million (2014-2019)
  • Table 109. Middle East Isothermal Nucleic Acid Amplification Technology Inaat, by End-User USD Million (2014-2019)
  • Table 110. Africa Isothermal Nucleic Acid Amplification Technology Inaat, by Type USD Million (2014-2019)
  • Table 111. Africa Isothermal Nucleic Acid Amplification Technology Inaat, by Application USD Million (2014-2019)
  • Table 112. Africa Isothermal Nucleic Acid Amplification Technology Inaat, by Technology USD Million (2014-2019)
  • Table 113. Africa Isothermal Nucleic Acid Amplification Technology Inaat, by End-User USD Million (2014-2019)
  • Table 114. North America Isothermal Nucleic Acid Amplification Technology Inaat, by Country USD Million (2014-2019)
  • Table 115. North America Isothermal Nucleic Acid Amplification Technology Inaat, by Type USD Million (2014-2019)
  • Table 116. North America Isothermal Nucleic Acid Amplification Technology Inaat, by Application USD Million (2014-2019)
  • Table 117. North America Isothermal Nucleic Acid Amplification Technology Inaat, by Technology USD Million (2014-2019)
  • Table 118. North America Isothermal Nucleic Acid Amplification Technology Inaat, by End-User USD Million (2014-2019)
  • Table 119. United States Isothermal Nucleic Acid Amplification Technology Inaat, by Type USD Million (2014-2019)
  • Table 120. United States Isothermal Nucleic Acid Amplification Technology Inaat, by Application USD Million (2014-2019)
  • Table 121. United States Isothermal Nucleic Acid Amplification Technology Inaat, by Technology USD Million (2014-2019)
  • Table 122. United States Isothermal Nucleic Acid Amplification Technology Inaat, by End-User USD Million (2014-2019)
  • Table 123. Canada Isothermal Nucleic Acid Amplification Technology Inaat, by Type USD Million (2014-2019)
  • Table 124. Canada Isothermal Nucleic Acid Amplification Technology Inaat, by Application USD Million (2014-2019)
  • Table 125. Canada Isothermal Nucleic Acid Amplification Technology Inaat, by Technology USD Million (2014-2019)
  • Table 126. Canada Isothermal Nucleic Acid Amplification Technology Inaat, by End-User USD Million (2014-2019)
  • Table 127. Mexico Isothermal Nucleic Acid Amplification Technology Inaat, by Type USD Million (2014-2019)
  • Table 128. Mexico Isothermal Nucleic Acid Amplification Technology Inaat, by Application USD Million (2014-2019)
  • Table 129. Mexico Isothermal Nucleic Acid Amplification Technology Inaat, by Technology USD Million (2014-2019)
  • Table 130. Mexico Isothermal Nucleic Acid Amplification Technology Inaat, by End-User USD Million (2014-2019)
  • Table 131. Isothermal Nucleic Acid Amplification Technology Inaat: by Type(USD/Units)
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. Isothermal Nucleic Acid Amplification Technology Inaat: by Type(USD Million)
  • Table 144. Isothermal Nucleic Acid Amplification Technology Inaat Instruments , by Region USD Million (2020-2025)
  • Table 145. Isothermal Nucleic Acid Amplification Technology Inaat Reagents , by Region USD Million (2020-2025)
  • Table 146. Isothermal Nucleic Acid Amplification Technology Inaat: by Application(USD Million)
  • Table 147. Isothermal Nucleic Acid Amplification Technology Inaat Infectious Disease Diagnosis [HIV, Influenza] , by Region USD Million (2020-2025)
  • Table 148. Isothermal Nucleic Acid Amplification Technology Inaat Blood Screening , by Region USD Million (2020-2025)
  • Table 149. Isothermal Nucleic Acid Amplification Technology Inaat Others , by Region USD Million (2020-2025)
  • Table 150. Isothermal Nucleic Acid Amplification Technology Inaat: by Technology(USD Million)
  • Table 151. Isothermal Nucleic Acid Amplification Technology Inaat Helicase-dependent Amplification (HDA) , by Region USD Million (2020-2025)
  • Table 152. Isothermal Nucleic Acid Amplification Technology Inaat Nicking Enzyme Amplification Reaction (NEAR) , by Region USD Million (2020-2025)
  • Table 153. Isothermal Nucleic Acid Amplification Technology Inaat Loop-mediated Isothermal Amplification (LAMP) , by Region USD Million (2020-2025)
  • Table 154. Isothermal Nucleic Acid Amplification Technology Inaat Strand Displacement Amplification (SDA) , by Region USD Million (2020-2025)
  • Table 155. Isothermal Nucleic Acid Amplification Technology Inaat Nucleic Acid Sequence-based Amplification (NASBA) , by Region USD Million (2020-2025)
  • Table 156. Isothermal Nucleic Acid Amplification Technology Inaat Transcription Mediated Amplification (TMA) , by Region USD Million (2020-2025)
  • Table 157. Isothermal Nucleic Acid Amplification Technology Inaat Single Primer Isothermal Amplification (SPIA) , by Region USD Million (2020-2025)
  • Table 158. Isothermal Nucleic Acid Amplification Technology Inaat Other Technologies , by Region USD Million (2020-2025)
  • Table 159. Isothermal Nucleic Acid Amplification Technology Inaat: by End-User(USD Million)
  • Table 160. Isothermal Nucleic Acid Amplification Technology Inaat Hospital , by Region USD Million (2020-2025)
  • Table 161. Isothermal Nucleic Acid Amplification Technology Inaat Clinic , by Region USD Million (2020-2025)
  • Table 162. Isothermal Nucleic Acid Amplification Technology Inaat Research Institute , by Region USD Million (2020-2025)
  • Table 163. Isothermal Nucleic Acid Amplification Technology Inaat Others , by Region USD Million (2020-2025)
  • Table 164. South America Isothermal Nucleic Acid Amplification Technology Inaat, by Country USD Million (2020-2025)
  • Table 165. South America Isothermal Nucleic Acid Amplification Technology Inaat, by Type USD Million (2020-2025)
  • Table 166. South America Isothermal Nucleic Acid Amplification Technology Inaat, by Application USD Million (2020-2025)
  • Table 167. South America Isothermal Nucleic Acid Amplification Technology Inaat, by Technology USD Million (2020-2025)
  • Table 168. South America Isothermal Nucleic Acid Amplification Technology Inaat, by End-User USD Million (2020-2025)
  • Table 169. Brazil Isothermal Nucleic Acid Amplification Technology Inaat, by Type USD Million (2020-2025)
  • Table 170. Brazil Isothermal Nucleic Acid Amplification Technology Inaat, by Application USD Million (2020-2025)
  • Table 171. Brazil Isothermal Nucleic Acid Amplification Technology Inaat, by Technology USD Million (2020-2025)
  • Table 172. Brazil Isothermal Nucleic Acid Amplification Technology Inaat, by End-User USD Million (2020-2025)
  • Table 173. Argentina Isothermal Nucleic Acid Amplification Technology Inaat, by Type USD Million (2020-2025)
  • Table 174. Argentina Isothermal Nucleic Acid Amplification Technology Inaat, by Application USD Million (2020-2025)
  • Table 175. Argentina Isothermal Nucleic Acid Amplification Technology Inaat, by Technology USD Million (2020-2025)
  • Table 176. Argentina Isothermal Nucleic Acid Amplification Technology Inaat, by End-User USD Million (2020-2025)
  • Table 177. Rest of South America Isothermal Nucleic Acid Amplification Technology Inaat, by Type USD Million (2020-2025)
  • Table 178. Rest of South America Isothermal Nucleic Acid Amplification Technology Inaat, by Application USD Million (2020-2025)
  • Table 179. Rest of South America Isothermal Nucleic Acid Amplification Technology Inaat, by Technology USD Million (2020-2025)
  • Table 180. Rest of South America Isothermal Nucleic Acid Amplification Technology Inaat, by End-User USD Million (2020-2025)
  • Table 181. Asia Pacific Isothermal Nucleic Acid Amplification Technology Inaat, by Country USD Million (2020-2025)
  • Table 182. Asia Pacific Isothermal Nucleic Acid Amplification Technology Inaat, by Type USD Million (2020-2025)
  • Table 183. Asia Pacific Isothermal Nucleic Acid Amplification Technology Inaat, by Application USD Million (2020-2025)
  • Table 184. Asia Pacific Isothermal Nucleic Acid Amplification Technology Inaat, by Technology USD Million (2020-2025)
  • Table 185. Asia Pacific Isothermal Nucleic Acid Amplification Technology Inaat, by End-User USD Million (2020-2025)
  • Table 186. China Isothermal Nucleic Acid Amplification Technology Inaat, by Type USD Million (2020-2025)
  • Table 187. China Isothermal Nucleic Acid Amplification Technology Inaat, by Application USD Million (2020-2025)
  • Table 188. China Isothermal Nucleic Acid Amplification Technology Inaat, by Technology USD Million (2020-2025)
  • Table 189. China Isothermal Nucleic Acid Amplification Technology Inaat, by End-User USD Million (2020-2025)
  • Table 190. Japan Isothermal Nucleic Acid Amplification Technology Inaat, by Type USD Million (2020-2025)
  • Table 191. Japan Isothermal Nucleic Acid Amplification Technology Inaat, by Application USD Million (2020-2025)
  • Table 192. Japan Isothermal Nucleic Acid Amplification Technology Inaat, by Technology USD Million (2020-2025)
  • Table 193. Japan Isothermal Nucleic Acid Amplification Technology Inaat, by End-User USD Million (2020-2025)
  • Table 194. India Isothermal Nucleic Acid Amplification Technology Inaat, by Type USD Million (2020-2025)
  • Table 195. India Isothermal Nucleic Acid Amplification Technology Inaat, by Application USD Million (2020-2025)
  • Table 196. India Isothermal Nucleic Acid Amplification Technology Inaat, by Technology USD Million (2020-2025)
  • Table 197. India Isothermal Nucleic Acid Amplification Technology Inaat, by End-User USD Million (2020-2025)
  • Table 198. South Korea Isothermal Nucleic Acid Amplification Technology Inaat, by Type USD Million (2020-2025)
  • Table 199. South Korea Isothermal Nucleic Acid Amplification Technology Inaat, by Application USD Million (2020-2025)
  • Table 200. South Korea Isothermal Nucleic Acid Amplification Technology Inaat, by Technology USD Million (2020-2025)
  • Table 201. South Korea Isothermal Nucleic Acid Amplification Technology Inaat, by End-User USD Million (2020-2025)
  • Table 202. Taiwan Isothermal Nucleic Acid Amplification Technology Inaat, by Type USD Million (2020-2025)
  • Table 203. Taiwan Isothermal Nucleic Acid Amplification Technology Inaat, by Application USD Million (2020-2025)
  • Table 204. Taiwan Isothermal Nucleic Acid Amplification Technology Inaat, by Technology USD Million (2020-2025)
  • Table 205. Taiwan Isothermal Nucleic Acid Amplification Technology Inaat, by End-User USD Million (2020-2025)
  • Table 206. Australia Isothermal Nucleic Acid Amplification Technology Inaat, by Type USD Million (2020-2025)
  • Table 207. Australia Isothermal Nucleic Acid Amplification Technology Inaat, by Application USD Million (2020-2025)
  • Table 208. Australia Isothermal Nucleic Acid Amplification Technology Inaat, by Technology USD Million (2020-2025)
  • Table 209. Australia Isothermal Nucleic Acid Amplification Technology Inaat, by End-User USD Million (2020-2025)
  • Table 210. Rest of Asia-Pacific Isothermal Nucleic Acid Amplification Technology Inaat, by Type USD Million (2020-2025)
  • Table 211. Rest of Asia-Pacific Isothermal Nucleic Acid Amplification Technology Inaat, by Application USD Million (2020-2025)
  • Table 212. Rest of Asia-Pacific Isothermal Nucleic Acid Amplification Technology Inaat, by Technology USD Million (2020-2025)
  • Table 213. Rest of Asia-Pacific Isothermal Nucleic Acid Amplification Technology Inaat, by End-User USD Million (2020-2025)
  • Table 214. Europe Isothermal Nucleic Acid Amplification Technology Inaat, by Country USD Million (2020-2025)
  • Table 215. Europe Isothermal Nucleic Acid Amplification Technology Inaat, by Type USD Million (2020-2025)
  • Table 216. Europe Isothermal Nucleic Acid Amplification Technology Inaat, by Application USD Million (2020-2025)
  • Table 217. Europe Isothermal Nucleic Acid Amplification Technology Inaat, by Technology USD Million (2020-2025)
  • Table 218. Europe Isothermal Nucleic Acid Amplification Technology Inaat, by End-User USD Million (2020-2025)
  • Table 219. Germany Isothermal Nucleic Acid Amplification Technology Inaat, by Type USD Million (2020-2025)
  • Table 220. Germany Isothermal Nucleic Acid Amplification Technology Inaat, by Application USD Million (2020-2025)
  • Table 221. Germany Isothermal Nucleic Acid Amplification Technology Inaat, by Technology USD Million (2020-2025)
  • Table 222. Germany Isothermal Nucleic Acid Amplification Technology Inaat, by End-User USD Million (2020-2025)
  • Table 223. France Isothermal Nucleic Acid Amplification Technology Inaat, by Type USD Million (2020-2025)
  • Table 224. France Isothermal Nucleic Acid Amplification Technology Inaat, by Application USD Million (2020-2025)
  • Table 225. France Isothermal Nucleic Acid Amplification Technology Inaat, by Technology USD Million (2020-2025)
  • Table 226. France Isothermal Nucleic Acid Amplification Technology Inaat, by End-User USD Million (2020-2025)
  • Table 227. Italy Isothermal Nucleic Acid Amplification Technology Inaat, by Type USD Million (2020-2025)
  • Table 228. Italy Isothermal Nucleic Acid Amplification Technology Inaat, by Application USD Million (2020-2025)
  • Table 229. Italy Isothermal Nucleic Acid Amplification Technology Inaat, by Technology USD Million (2020-2025)
  • Table 230. Italy Isothermal Nucleic Acid Amplification Technology Inaat, by End-User USD Million (2020-2025)
  • Table 231. United Kingdom Isothermal Nucleic Acid Amplification Technology Inaat, by Type USD Million (2020-2025)
  • Table 232. United Kingdom Isothermal Nucleic Acid Amplification Technology Inaat, by Application USD Million (2020-2025)
  • Table 233. United Kingdom Isothermal Nucleic Acid Amplification Technology Inaat, by Technology USD Million (2020-2025)
  • Table 234. United Kingdom Isothermal Nucleic Acid Amplification Technology Inaat, by End-User USD Million (2020-2025)
  • Table 235. Netherlands Isothermal Nucleic Acid Amplification Technology Inaat, by Type USD Million (2020-2025)
  • Table 236. Netherlands Isothermal Nucleic Acid Amplification Technology Inaat, by Application USD Million (2020-2025)
  • Table 237. Netherlands Isothermal Nucleic Acid Amplification Technology Inaat, by Technology USD Million (2020-2025)
  • Table 238. Netherlands Isothermal Nucleic Acid Amplification Technology Inaat, by End-User USD Million (2020-2025)
  • Table 239. Rest of Europe Isothermal Nucleic Acid Amplification Technology Inaat, by Type USD Million (2020-2025)
  • Table 240. Rest of Europe Isothermal Nucleic Acid Amplification Technology Inaat, by Application USD Million (2020-2025)
  • Table 241. Rest of Europe Isothermal Nucleic Acid Amplification Technology Inaat, by Technology USD Million (2020-2025)
  • Table 242. Rest of Europe Isothermal Nucleic Acid Amplification Technology Inaat, by End-User USD Million (2020-2025)
  • Table 243. MEA Isothermal Nucleic Acid Amplification Technology Inaat, by Country USD Million (2020-2025)
  • Table 244. MEA Isothermal Nucleic Acid Amplification Technology Inaat, by Type USD Million (2020-2025)
  • Table 245. MEA Isothermal Nucleic Acid Amplification Technology Inaat, by Application USD Million (2020-2025)
  • Table 246. MEA Isothermal Nucleic Acid Amplification Technology Inaat, by Technology USD Million (2020-2025)
  • Table 247. MEA Isothermal Nucleic Acid Amplification Technology Inaat, by End-User USD Million (2020-2025)
  • Table 248. Middle East Isothermal Nucleic Acid Amplification Technology Inaat, by Type USD Million (2020-2025)
  • Table 249. Middle East Isothermal Nucleic Acid Amplification Technology Inaat, by Application USD Million (2020-2025)
  • Table 250. Middle East Isothermal Nucleic Acid Amplification Technology Inaat, by Technology USD Million (2020-2025)
  • Table 251. Middle East Isothermal Nucleic Acid Amplification Technology Inaat, by End-User USD Million (2020-2025)
  • Table 252. Africa Isothermal Nucleic Acid Amplification Technology Inaat, by Type USD Million (2020-2025)
  • Table 253. Africa Isothermal Nucleic Acid Amplification Technology Inaat, by Application USD Million (2020-2025)
  • Table 254. Africa Isothermal Nucleic Acid Amplification Technology Inaat, by Technology USD Million (2020-2025)
  • Table 255. Africa Isothermal Nucleic Acid Amplification Technology Inaat, by End-User USD Million (2020-2025)
  • Table 256. North America Isothermal Nucleic Acid Amplification Technology Inaat, by Country USD Million (2020-2025)
  • Table 257. North America Isothermal Nucleic Acid Amplification Technology Inaat, by Type USD Million (2020-2025)
  • Table 258. North America Isothermal Nucleic Acid Amplification Technology Inaat, by Application USD Million (2020-2025)
  • Table 259. North America Isothermal Nucleic Acid Amplification Technology Inaat, by Technology USD Million (2020-2025)
  • Table 260. North America Isothermal Nucleic Acid Amplification Technology Inaat, by End-User USD Million (2020-2025)
  • Table 261. United States Isothermal Nucleic Acid Amplification Technology Inaat, by Type USD Million (2020-2025)
  • Table 262. United States Isothermal Nucleic Acid Amplification Technology Inaat, by Application USD Million (2020-2025)
  • Table 263. United States Isothermal Nucleic Acid Amplification Technology Inaat, by Technology USD Million (2020-2025)
  • Table 264. United States Isothermal Nucleic Acid Amplification Technology Inaat, by End-User USD Million (2020-2025)
  • Table 265. Canada Isothermal Nucleic Acid Amplification Technology Inaat, by Type USD Million (2020-2025)
  • Table 266. Canada Isothermal Nucleic Acid Amplification Technology Inaat, by Application USD Million (2020-2025)
  • Table 267. Canada Isothermal Nucleic Acid Amplification Technology Inaat, by Technology USD Million (2020-2025)
  • Table 268. Canada Isothermal Nucleic Acid Amplification Technology Inaat, by End-User USD Million (2020-2025)
  • Table 269. Mexico Isothermal Nucleic Acid Amplification Technology Inaat, by Type USD Million (2020-2025)
  • Table 270. Mexico Isothermal Nucleic Acid Amplification Technology Inaat, by Application USD Million (2020-2025)
  • Table 271. Mexico Isothermal Nucleic Acid Amplification Technology Inaat, by Technology USD Million (2020-2025)
  • Table 272. Mexico Isothermal Nucleic Acid Amplification Technology Inaat, by End-User USD Million (2020-2025)
  • Table 273. Isothermal Nucleic Acid Amplification Technology Inaat: by Type(USD/Units)
  • Table 274. Research Programs/Design for This Report
  • Table 275. Key Data Information from Secondary Sources
  • Table 276. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Isothermal Nucleic Acid Amplification Technology Inaat: by Type USD Million (2014-2019)
  • Figure 5. Global Isothermal Nucleic Acid Amplification Technology Inaat: by Application USD Million (2014-2019)
  • Figure 6. Global Isothermal Nucleic Acid Amplification Technology Inaat: by Technology USD Million (2014-2019)
  • Figure 7. Global Isothermal Nucleic Acid Amplification Technology Inaat: by End-User USD Million (2014-2019)
  • Figure 8. South America Isothermal Nucleic Acid Amplification Technology Inaat Share (%), by Country
  • Figure 9. Asia Pacific Isothermal Nucleic Acid Amplification Technology Inaat Share (%), by Country
  • Figure 10. Europe Isothermal Nucleic Acid Amplification Technology Inaat Share (%), by Country
  • Figure 11. MEA Isothermal Nucleic Acid Amplification Technology Inaat Share (%), by Country
  • Figure 12. North America Isothermal Nucleic Acid Amplification Technology Inaat Share (%), by Country
  • Figure 13. Global Isothermal Nucleic Acid Amplification Technology Inaat: by Type USD/Units (2014-2019)
  • Figure 14. Global Isothermal Nucleic Acid Amplification Technology Inaat share by Players 2019 (%)
  • Figure 15. Global Isothermal Nucleic Acid Amplification Technology Inaat share by Players (Top 3) 2019(%)
  • Figure 16. Global Isothermal Nucleic Acid Amplification Technology Inaat share by Players (Top 5) 2019(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Grifols S.A. (Spain) Revenue, Net Income and Gross profit
  • Figure 19. Grifols S.A. (Spain) Revenue: by Geography 2019
  • Figure 20. Hologic, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. Hologic, Inc. (United States) Revenue: by Geography 2019
  • Figure 22. Abbott Laboratories, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. Abbott Laboratories, Inc. (United States) Revenue: by Geography 2019
  • Figure 24. Becton, Dickinson & Company (United States) Revenue, Net Income and Gross profit
  • Figure 25. Becton, Dickinson & Company (United States) Revenue: by Geography 2019
  • Figure 26. Quidel Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 27. Quidel Corporation (United States) Revenue: by Geography 2019
  • Figure 28. Meridian Bioscience (United States) Revenue, Net Income and Gross profit
  • Figure 29. Meridian Bioscience (United States) Revenue: by Geography 2019
  • Figure 30. Eiken Chemical Co. Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 31. Eiken Chemical Co. Ltd. (Japan) Revenue: by Geography 2019
  • Figure 32. Lucigen Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 33. Lucigen Corporation (United States) Revenue: by Geography 2019
  • Figure 34. OptiGene Limited (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 35. OptiGene Limited (United Kingdom) Revenue: by Geography 2019
  • Figure 36. BioMerieux SA (France) Revenue, Net Income and Gross profit
  • Figure 37. BioMerieux SA (France) Revenue: by Geography 2019
  • Figure 38. Qiagen (Netherlands) Revenue, Net Income and Gross profit
  • Figure 39. Qiagen (Netherlands) Revenue: by Geography 2019
  • Figure 40. Global Isothermal Nucleic Acid Amplification Technology Inaat: by Type USD Million (2020-2025)
  • Figure 41. Global Isothermal Nucleic Acid Amplification Technology Inaat: by Application USD Million (2020-2025)
  • Figure 42. Global Isothermal Nucleic Acid Amplification Technology Inaat: by Technology USD Million (2020-2025)
  • Figure 43. Global Isothermal Nucleic Acid Amplification Technology Inaat: by End-User USD Million (2020-2025)
  • Figure 44. South America Isothermal Nucleic Acid Amplification Technology Inaat Share (%), by Country
  • Figure 45. Asia Pacific Isothermal Nucleic Acid Amplification Technology Inaat Share (%), by Country
  • Figure 46. Europe Isothermal Nucleic Acid Amplification Technology Inaat Share (%), by Country
  • Figure 47. MEA Isothermal Nucleic Acid Amplification Technology Inaat Share (%), by Country
  • Figure 48. North America Isothermal Nucleic Acid Amplification Technology Inaat Share (%), by Country
  • Figure 49. Global Isothermal Nucleic Acid Amplification Technology Inaat: by Type USD/Units (2020-2025)
Some of the key companies/manufacturers profiled in the report
  • Grifols S.A. (Spain)
  • Hologic, Inc. (United States)
  • Abbott Laboratories, Inc. (United States)
  • Becton, Dickinson & Company (United States)
  • Quidel Corporation (United States)
  • Meridian Bioscience (United States)
  • Eiken Chemical Co. Ltd. (Japan)
  • Lucigen Corporation (United States)
  • OptiGene Limited (United Kingdom)
  • bioMerieux SA (France)
  • Qiagen (Netherlands)
Additional players considered in the study are as follows:
Sysmex Corporation (Japan) , PREMIER Biosoft (United States) , mFluiDx (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation